BioMarin Pharmaceuticals BMRN Other Accounts Payable and Accrued Liabilities
Other Accounts Payable and Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAccountsPayableAndAccruedLiabilities.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's other accounts payable and accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's other accounts payable and accrued liabilities?
- BioMarin Pharmaceuticals (BMRN) reported other accounts payable and accrued liabilities of $7.29M in Q1 2026.
- How has BioMarin Pharmaceuticals's other accounts payable and accrued liabilities changed year-over-year?
- BioMarin Pharmaceuticals's other accounts payable and accrued liabilities decreased by 39.3% year-over-year, from $12.02M to $7.29M.
- What is the long-term trend for BioMarin Pharmaceuticals's other accounts payable and accrued liabilities?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's other accounts payable and accrued liabilities has grown at a 10.6% compound annual growth rate (CAGR), from $4.64M to $7.68M.